By
Download on the App Store

episodes

  • Volume 6, Number 6
    Daniel Heintz, MD and Karen McCoy, MD cover the important topic of Trends in Inhaled Antibiotic Therapy in the format of case-study scenarios for the clinical practice.
    29 min
  • Volume 6, Number 2
    In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice.
    23 min
  • Special Edition 2015, Part 4
    Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen's University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice.
    7 min
  • Special Edition 2015, Part 3
    Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children's Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice.
    6 min
  • Special Edition 2015, Part 1
    Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice.
    12 min
  • Special Edition 2015, Part 2
    Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice.
    6 min
  • Volume 5, Number 14
    In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis, and evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis.
    34 min
  • Volume 5, Number 12
    In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases.
    27 min
  • Volume 5, Number 10
    In this issue of eCystifibrosis Review we will be join by Dr. Stuart Elborn of Queens University in Belfast, Northern Ireland. Dr. Elborn discusses the effects of CFTR-Modifying Therapies. He will present three patient-case scenarios and identify appropriate treatment options.
    33 min